INNOCARE released its 2025 Environmental, Social and Governance (ESG) Report, outlining the group’s first year of profitability, significant environmental gains and continued investment in innovation.
Financial and R&D Highlights • 2025 marked the company’s inaugural profitable year. • R&D expenditure reached RMB 951.60 million, representing 40.07 % of operating revenue. • The pipeline advanced to three commercialised products in China—orelabrutinib, tafasitamab and zurletrectinib—alongside multiple registrational trials in haematology, autoimmune diseases and solid tumours. • During the year, 41 patent applications were filed and 43 patents were granted across several jurisdictions.
Environmental Performance • Energy-use intensity fell 57.71 % versus 2023, while total greenhouse-gas intensity (Scope 1 + 2) declined 60.75 % to 0.05 tCO₂e per RMB 10,000 of revenue. • Industrial wastewater-discharge intensity dropped 61.31 % from 2023. • Waste-gas and waste-disposal compliance rates were maintained at 100 %, and no environmental penalties were recorded. • The company reconfirmed its targets to cut both energy and carbon intensity by 10 % from the 2023 base by 2028—targets already exceeded in 2025.
Social Metrics • The workforce totalled 1,297 employees; women accounted for 52 % of headcount and 57 % of directors. • Employee-training investment reached RMB 8.67 million, delivering 25,940 training attendances and averaging 49.22 training hours per employee. • Zero work-related fatalities, injuries or occupational-disease cases were reported; safe working hours accumulated 5.11 million. • Public-welfare spending rose 16 % year-on-year to RMB 2.37 million, directed mainly toward rural revitalisation, education and patient assistance.
Governance and Compliance • Independent directors constituted 43 % of the board; women held 57 % of seats. • There were no corruption, unfair-competition or major litigation cases, and the Shanghai Stock Exchange awarded the firm its top-tier “Class A” disclosure rating. • Twenty-six specialised compliance-training sessions reached 2,173 employee attendances.
Product Quality and Patient Access • No adverse-reaction clusters or product recalls occurred; customer-complaint resolution stood at 100 %. • Orelabrutinib gained first-line CLL/SLL approval and secured inclusion in China’s National Reimbursement Drug List, bolstering drug affordability. • New patient-assistance programmes for tafasitamab and zurletrectinib were initiated in December 2025.
Outlook Chairman & CEO Jisong Cui reiterated the “innovation-led” strategy and confirmed that INNOCARE will maintain high R&D intensity, expand global clinical programmes and embed ESG metrics into corporate decision-making as the group progresses through its “InnoCare 2.0” growth phase.